APA (7th ed.) Citation

Zhang, Y., Wei, R., Song, G., Yang, X., Zhang, M., Liu, W., . . . Shan, Y. Insights into the mechanisms of serplulimab: A distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Zhang, Yizhou, et al. Insights into the Mechanisms of Serplulimab: A Distinctive Anti-PD-1 Monoclonal Antibody, in Combination with a TIGIT or LAG3 Inhibitor in Preclinical Tumor Immunotherapy Studies. Taylor & Francis Group.

MLA (9th ed.) Citation

Zhang, Yizhou, et al. Insights into the Mechanisms of Serplulimab: A Distinctive Anti-PD-1 Monoclonal Antibody, in Combination with a TIGIT or LAG3 Inhibitor in Preclinical Tumor Immunotherapy Studies. Taylor & Francis Group.